Renal Cell Carcinoma
Renal Cell Carcinoma
Advertisement
Emily MenendezLocalized Renal Cell Carcinoma | March 23, 2023
SAbR could potentially serve as a new noninvasive alternative treatment, but data on the procedure are limited.
Read More
Sangeeta Goswami, MD, PhDUrothelial Carcinoma | March 21, 2023
Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer.
Emily MenendezAdvanced Renal Cell Carcinoma | March 17, 2023
Patients with accRCC were assigned to receive either a conventional continuation strategy or a drug-free interval strategy.
Brian Rini, MD, FASCOVideo Insights | March 16, 2023
In the final segment of a debate series, Brian Rini, MD, and Monty Pal, MD, debate RCC adjuvant therapeutic options.
Brian Rini, MD, FASCORoundtable | March 15, 2023
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
Brian Rini, MD, FASCORoundtable | March 15, 2023
The panel discusses triplet combinations in development for RCC.
Brian Rini, MD, FASCORoundtable | March 15, 2023
The panel discusses the disappointing results of the COSMIC-313 trial.
Monty Pal, MDRoundtable | March 15, 2023
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
Monty Pal, MDRoundtable | March 15, 2023
The panel shares how they treat frontline papillary kidney cancer.
Brian Rini, MD, FASCOVideo Insights | March 15, 2023
In the second segment of a debate series, Drs. Rini and Pal address kidney cancer clinical trials of interest.
Brian Rini, MD, FASCORoundtable | March 14, 2023
The panel discusses treatment-related toxicities and when to consider stopping treatment.
Monty Pal, MDRoundtable | March 14, 2023
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
Brian Rini, MD, FASCOVideo Insights | March 14, 2023
In a debate series between Brian Rini, MD, and Monty Pal, MD, they discuss frontline RCC treatment options.
Emily MenendezLocalized Renal Cell Carcinoma | March 10, 2023
A review of adjuvant therapies shows patient characteristics that may result in favorable treatment responses.
Emily MenendezAdvanced Renal Cell Carcinoma | March 10, 2023
Plasma and urine free glycosaminoglycan profiles—or GAGomes—can potentially be used as metabolic biomarkers for mRCC.
Brian Rini, MD, FASCORenal Cell Carcinoma | March 10, 2023
The panel compares three treatment regimens.
Monty Pal, MDRoundtable | March 10, 2023
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
Brian Rini, MD, FASCORoundtable | March 10, 2023
The panel discusses the CheckMate 8Y8 clinical trial.
Monty Pal, MDRoundtable | March 10, 2023
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
Pavlos Msaouel, MD, PhDRenal Cell Carcinoma | March 10, 2023
Dr. Msaouel provides an overview of the molecular characteristics and treatment for nccRCC, with a particular focus on RMC.
Advertisement
Advertisement
Advertisement